Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Reporting

Note 14 – Segment Reporting

The Company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. Since the Company operates in a single segment, the measure of segment total assets and loss from operations is the same as that reported on the accompanying balance sheets as total assets, and the accompanying statement of operations as loss from operations, respectively.

The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM uses operating expenses to measure performance against progress in its clinical trials and its product development. The following table sets forth segment expenses.

	December 31,
(In thousands)	2024			2023
Research and Development:
Employee expense	$	4,984		$	4,004
Clinical		5,345			7,567
Product		1,147			1,443
Other		773			569
Total research and development		12,249			13,583
Selling, general and administrative expense
Employee expense	$	6,285			7,436
Professional fees		2,451			1,729
Occupancy		626			631
Insurance		655			724
Other		1,560			1,135
Total selling, general and administrative expense		11,577			11,655
Loss from Operations		23,826			25,238
Adjustments and reconciling Items		(2,007	)		(1,722	)
Net Loss	$	21,819		$	23,516

Adjustments and reconciling items in the above table consist of interest income and realized and unrealized gains and losses related to our investments in US Treasury securities.